BackTable Urology
Ep. 193 Bladder Cancer Innovations: ESMO 2024 Highlights with Dr. Andrea Apolo
Dr. Andrea Apolo
Well, just that I think time will tell in terms of the rest of the outcomes of that trial and their other trials. Also, that we're awaiting their data that include platinum-based, cisplatinum-based chemotherapy in combination with with a checkpoint inhibitor, including the Energize study with nivolumab. And we also have the Keynote 866 study with pembrolizumab.
0
💬
0
Comments
Log in to comment.
There are no comments yet.